The net profit of the Cologne pharmaceutical industry increased by more than 50% to 10 ext. 10 5

Cologne pharmaceutical Industry (002422) March 6 Evening announced the annual report, the company 2010 to achieve business income of 4.026 billion yuan, an increase of 24.04%, to achieve the ownership of the listed company's shareholders of the net profit of 661 million yuan, an increase of 54.55%, the basic earnings per share 3.08 yuan, the year-on-year increase of 29.41%.　　The annual report shows that the company's 2010 profit distribution scheme is to be based on the 240 million shares of the company's total share capital at the end of 2010, with a cash dividend of 5 yuan (including tax) to all shareholders and 10 shares per shareholder, and 10 shares per 10 share of Capital Provident Fund. The company also announced that the company intends to register in the National Interbank bond market The total amount does not exceed the company's latest issue of the combined audit of the net assets (including minority rights and interests) 40% of non-financial Enterprise debt financing tools, and is intended to be issued in the period of registration, mainly to supplement the company's production and operation Funds,　　Investment in project construction and adjustment of debt structure. The company also announced that, according to the business development process to optimize the management structure, improve management efficiency and integration of resources needs, the company plans to the wholly-owned subsidiary of Sichuan Pearl Pharmaceutical Co., Ltd. to implement absorption merger.